On Mar. 3, 2021, Resverlogix and QIMR Berghofer Medical Research Institute announced the publishing of an article providing evidence of apabetalone’s potential benefit on SARS-CoV-2 (COVID-19). The article was published on the pre-print server, bioRxiv, at the request of the reviewing scientific journal.

Apabetalone, a FDA granted Breakthrough Therapy Designation (BTD) drug is an investigational, phase 3 clinical candidate with safety data in more than 4,000 subjects. Resverlogix previously announced plans for an open-label study to assess the safety and efficacy of apabetalone in the treatment of COVID-19.